Berobenatide is named as an intervention in 11 current clinical trials in our USA, Canada, Japan, UK, Germany, Spain, Poland, Czechia, Brazil, South Korea and China registers. 3 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Pfizer. The most-studied condition is Obesity. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Berobenatide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)
2026-525318-75-00 · Nutritional and Metabolic Diseases
|
Phase 3 | Authorised | Pfizer Inc | Spain, France, Germany + 2 more |
|
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-
BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH
OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3,
MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL
(VESPER-5)
2025-523975-48-00 · CTIS ↗ · Nutritional and Metabolic Diseases
|
Phase 3 | Ongoing | Metsera Inc | Czechia, Bulgaria, Slovakia + 5 more |
|
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-
BIASED ULTRA LONG-ACTING GLP-1RA IN PEOPLE WITH
OVERWEIGHT OR OBESITY: A PHASE 3, MULTI-CENTER
RANDOMIZED, CONTROLLED TRIAL (VESPER-4)
2025-523974-18-00 · CTIS ↗ · Nutritional and Metabolic Diseases
|
Phase 3 | Ongoing | Metsera Inc | Germany, Hungary, Slovakia + 5 more |
| Lead sponsor | Trials |
|---|---|
| Pfizer | 11 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
11 current trials in our USA, Canada, Japan, UK, Germany, Spain, Poland, Czechia, Brazil, South Korea and China registers name Berobenatide (also registered as MET097) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 11 trials are recruiting: 3 with sites in USA, 1 with sites in Canada, 1 with sites in Japan, 1 with sites in Brazil and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Pfizer. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Berobenatide works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Berobenatide works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Berobenatide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.